Cooper Companies Stock (NASDAQ:COO)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$105.85

52W Range

$80.48 - $112.38

50D Avg

$106.56

200D Avg

$97.21

Market Cap

$20.88B

Avg Vol (3M)

$1.14M

Beta

0.98

Div Yield

$0.02

COO Company Profile


The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

15,000

IPO Date

Jan 21, 1983

Website

COO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceOct 23Oct 22Oct 21
Coopersurgical Segment$1.17B$633.60M$451.30M
Coopervision Segment$2.42B$737.40M$697.50M
CooperVision Segment$2.42B--
CooperSurgical Segment$1.17B--

Fiscal year ends in Oct 23 | Currency in USD

COO Financial Summary


Oct 23Oct 22Oct 21
Revenue$3.59B$3.31B$2.92B
Operating Income$533.10M$507.60M$505.80M
Net Income$294.20M$385.80M$2.94B
EBITDA$704.40M$712.10M$660.70M
Basic EPS-$7.83$59.80
Diluted EPS-$7.76$59.16

Fiscal year ends in Oct 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Aug 29, 24 | 5:59 AM
Q2 24May 30, 24 | 7:55 PM
Q1 24Feb 29, 24 | 12:00 AM

Peer Comparison


TickerCompany
MMSIMerit Medical Systems, Inc.
WSTWest Pharmaceutical Services, Inc.
BDXBecton, Dickinson and Company
RGENRepligen Corporation
HOLXHologic, Inc.
BLCOBausch + Lomb Corporation
RMDResMed Inc.
NVSTEnvista Holdings Corporation
ANGOAngioDynamics, Inc.
HAEHaemonetics Corporation
ICUIICU Medical, Inc.
ATRAptarGroup, Inc.
TFXTeleflex Incorporated